Shield Therapeutics PLC Update on Legal Proceedings (8490A)

TIDMSTX

RNS Number : 8490A

Shield Therapeutics PLC

03 June 2019

Shield Therapeutics plc

("Shield" or the "Group")

Update on Legal Proceedings

London, UK, 3 June 2019: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru(R), announces an update on legal proceedings with Teva Pharmaceutical Industries Ltd (TEVA).

Following the announcement to shareholders on 14 March 2019, Shield has received notice that TEVA has filed a notice of appeal to the Opposition Division of the European Patent Office's decision on Shield's patent #2 668 175, which covers a "Process for preparing an iron hydroxypyrone". No date has been set for the hearing.

Shield will continue to robustly defend its intellectual property and believes the Board of Appeal should uphold the first instance decision of the European Patent Office.

Shield will provide further updates to shareholders on proceedings as required.

- Ends -

For further information please contact:

 
 Shield Therapeutics plc                             www.shieldtherapeutics.com 
 Carl Sterritt, Chief Executive 
  Officer                                                   +44 (0)20 7186 8500 
 Tim Watts, Chief Financial 
  Officer 
 
 Nominated Advisor and Joint 
  Broker 
 Peel Hunt LLP 
 James Steel/Dr Christopher 
  Golden                                                    +44 (0)20 7418 8900 
 
 Joint Broker 
 finnCap Ltd                                                +44 (0)20 7220 0500 
 Geoff Nash /Matt Radley/ 
  Alice Lane 
 
 Financial PR & IR Advisor 
 Walbrook PR                       +44 (0)20 7933 8780 or shield@walbrookpr.com 
 Paul McManus / Anna Dunphy           +44 (0)7980 541 893 / +44 (0)7876 741 001

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R), for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru(R) is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27(th) July 2019. For more information please visit www.shieldtherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDDBGDLGDGBGCD

(END) Dow Jones Newswires

June 03, 2019 02:00 ET (06:00 GMT)

Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Oct 2024 to Nov 2024